Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.51 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 12/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315534 | 1.00 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL17090761 | 1.00 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL31723482 | 1.00 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL5502782 | 0.94 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL6850137 | 0.94 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL7068149 | 0.93 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL7068162 | 0.93 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL30216573 | 0.92 | TYMP (0.47) | TYMPTK1TK2 | |
| SCHEMBL22984025 | 0.92 | TYMP (0.54) | TYMPTK1TK2 | |
| SCHEMBL7702801 | 0.92 | TYMP (0.54) | TYMPTK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7002006-B2 | Protection of nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040158055-A1 | Protection of nucleosides | IONIS PHARMACEUTICALS, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | ISIS PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6610837-B1 | Preparation of an oligonucleotide compound of given formula by reacting with given compounds, followed by oxidation or sulfurization | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| WO-2000055179-A1 | NOVEL PHOSPHATE AND THIOPHOSPHATE PROTECTING GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040158055-A1 | Protection of nucleosides | RNASEL, ADAR, RNGTT | TYMP 11/4885TK1 54/4885TK2 259/4885 |
| US-20040082774-A1 | Novel phosphate and thiophosphate protecting groups | TYMP, MTAP, PPIP5K2 | TYMP 1/4885TK1 27/4885TK2 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.